immunogenicity of a booster dose of BNT162b2 administered 7 to 9 months after the primary two-dose series suggest that a third dose could prolong protection and further increase the breadth of protection.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: